| Patient | Howard Hughes |
|---|---|
| Date of birth | 1984-12-24 |
| Identifiers | MRN HR-ML006-SYN; SSN (made up) 000-06-5571 |
| Document date | 2026-05-11 |
| Author | Anselm Garrity-Moyo, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
One-week review of contamination fears and codeine use, seen the same day by psychiatry. [S]
Mr. Hughes returns one week after intake and is seen by Dr. Bachmann-Adeyemi of psychiatry on the same day. He took his last acetaminophen-codeine tablet about 20 hours ago, as planned for starting buprenorphine today, and has taken no more than the prescribed eight tablets a day this week. He has yawning, aching, a runny nose and gooseflesh. The contamination fears and washing are unchanged, at about four hours a day; he washed his hands eleven times before coming in. He completed the PCL-5 about the crash. The intake urine test, done with his consent, was positive for codeine and morphine, as expected, and negative for fentanyl, other opioids, benzodiazepines and other drugs. The prescription monitoring report showed acetaminophen-codeine from two prescribers at two pharmacies and no other controlled drugs. HIV, hepatitis C and hepatitis B tests were negative; he is not immune to hepatitis B. He has taken his unused codeine tablets to a pharmacy take-back. [S]
| Element | Detail |
|---|---|
| Last codeine | About 20 hours ago |
| Withdrawal | COWS 13, moderate |
| Rituals | About four hours a day; Y-BOCS 28 |
| Intake results | Urine positive for codeine and morphine only, negative for fentanyl; two prescribers on the monitoring report; HIV, hepatitis B and C negative; hepatitis B not immune |
| PCL-5 | 18, below the cut point |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Aching and restless since this morning |
| Gastrointestinal | Positive | Mild cramping; no vomiting or diarrhea |
| Musculoskeletal | Positive | Chest wall, left shoulder and low back pain |
| Psychiatric | Positive | Contamination fears and washing unchanged; no hallucinations; no thoughts of suicide or of harming anyone |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Acetaminophen 300 mg with codeine 30 mg oral tablet, prescribed elsewhere since the crash as one or two tablets every 6 hours as needed, no more than 8 a day; he has been taking 10 to 12 a day | One or two tablets every 6 hours as needed, no more than 8 a day | Oral route | 2026-05-04 to 2026-05-11 | completed | S |
| Naloxone 4 mg nasal spray, one spray into one nostril for a suspected opioid overdose, repeated every two to three minutes in the other nostril if needed; two-pack dispensed, with instruction for him and his household staff | One spray as needed for suspected overdose; repeat in 2 to 3 minutes if needed | Nasal route | 2026-05-04 | active | S |
| Buprenorphine 2 mg with naloxone 0.5 mg sublingual film for the first day: 4 mg once withdrawal is moderate (COWS 12 or more), then 2 to 4 mg every one to two hours as needed, to no more than 16 mg on the first day | First-day induction by the written plan, no more than 16 mg | Sublingual route | 2026-05-11 to 2026-05-12 | completed | S |
| Acetaminophen 500 mg oral tablet, two tablets three times daily (3,000 mg a day) for pain after the crash, now that codeine combination tablets have stopped | Two tablets three times daily, no more than 3,000 mg a day | Oral route | 2026-05-11 | active | S |
| Sertraline 50 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-05-11 to 2026-06-08 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-05-11 | Body height | 191 | cm | S |
| 2026-05-11 | Body weight | 72.3 | kg | S |
| 2026-05-11 | Body mass index (BMI) [Ratio] | 19.8 | kg/m2 | S |
| 2026-05-11 | Systolic blood pressure | 124 | mm[Hg] | S |
| 2026-05-11 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 2026-05-11 | Heart rate | 88 | /min | S |
| 2026-05-11 | Respiratory rate | 16 | /min | S |
| 2026-05-11 | Body temperature | 36.8 | Cel | S |
| 2026-05-11 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-05-11 | PTSD PCL-5 score [PCL-5] | 18 | {score} | S |
Vital signs recorded on 2026-05-11; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Alert, restless, yawning; blood pressure 124/80, pulse 88; weight 72.3 kg |
| Eyes | Pupils 5 mm, reactive; mild tearing |
| Skin | Gooseflesh on the arms; hands red and cracked from washing; healed burn scars |
| Musculoskeletal | Tenderness over healed rib fractures on the left; left shoulder elevation limited to 120 degrees by pain |
| Psychiatric | Anxious and courteous; contamination obsessions with washing and avoidance; says the fears are probably excessive; no psychotic features; no suicidal or homicidal ideation |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Intrusive fears of contamination by germs for about a year, worse since the crash, with hand washing, cleaning of objects and avoidance of handshakes, shared spaces and food handled by others, taking about four hours a day; he recognizes the fears are probably excessive; cause under evaluation | resolved | confirmed | R46.81 | S — Synthetic presenting problem anchored to his documented fear of germs; resolved into the diagnosis of OCD at the consultation. Not a claim about his real symptoms in 1947. |
| Obsessive-compulsive disorder, contamination type, with good or fair insight, not tic-related; Y-BOCS 28 (severe) at intake; no post-traumatic stress disorder on screening | active | confirmed | F42.2 | S — Synthetic modern diagnosis made at the consultation, linked to the retrospective interpretation of his documented fears (R). Not a claim about his real diagnosis. |
| Opioid use disorder, moderate (four of the DSM-5-TR criteria that count for a prescribed opioid: taking more than prescribed, failed attempts to cut down, time spent getting prescriptions from two prescribers, and craving), on codeine prescribed after a crash; buprenorphine planned | active | confirmed | F11.20 | S — Synthetic modern coding; tolerance and withdrawal are not counted for a medicine taken under medical supervision. Person-first language; not a claim about his real diagnosis. |
| Chronic pain after major trauma ten months ago (crushed chest with rib fractures, collapsed lung, other fractures and burns): chest wall, left shoulder and low back pain, PEG 6.7 | active | confirmed | G89.21 | S — Synthetic modern diagnosis anchored to his documented injuries. |
| Difficulty hearing conversation, worse in noise, after years of flying in loud aircraft; cause under evaluation | active | confirmed | H91.93 | S — Synthetic presenting problem; resolved into a diagnosis when audiometry was done at five weeks. His documented deafness is from later years. |
| Weight loss of about 8 kg since the crash (BMI 19.7), from eating little outside food he has prepared or inspected himself because of contamination fears | active | confirmed | R63.4 | S — Synthetic nutrition problem linked to the contamination fears; not a claim about his real weight in 1947. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | OCD severity (Y-BOCS, clinician-rated) and time spent on rituals | Every visit | Completed today | Y-BOCS 28 (obsessions 14, compulsions 14), confirmed by psychiatry; about four hours a day |
| Survey | Post-traumatic stress after the crash (PCL-5) | Once, at diagnosis | Completed today | PCL-5 18, below the cut point of 31 to 33; no post-traumatic stress disorder |
| Medication safety | SSRI tolerability and adherence: side effects, sodium, bleeding risk, activation or new suicidal thoughts | Every visit, and two weeks after each start or dose change | Completed today | Baseline before sertraline: sodium 139 mmol/L at intake, no anticoagulant or NSAID, no history of mania; told to report restlessness or any new thoughts of suicide |
| Referral | Exposure and response prevention: sessions attended and home practice | Weekly, then twice weekly | Ordered | Weekly sessions with the clinic psychologist booked from next week |
| Self-management | Accommodation by staff, reduced step by step with his consent | Every visit | Ordered | Written consent signed for his assistant to join two sessions; staff will not be asked to report on him |
| Survey | Depression (PHQ-9) and anxiety (GAD-7) | At baseline and at least monthly during acute treatment | Up to date | PHQ-9 9 (item 9 scored 0) and GAD-7 12 at intake; repeat at five weeks |
| Survey | Suicide risk review, safety plan and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or of harming anyone; 988 in his phone; codeine taken to the take-back |
| Self-management | Opioid use and cravings (his own account), buprenorphine adherence and side effects (sedation, constipation) | Every visit | Completed today | No more than eight codeine tablets a day this week; last dose 20 hours ago; COWS 13; buprenorphine started in clinic |
| Laboratory | Urine drug test with fentanyl and buprenorphine, with consent | At start, then about monthly in the first months | Up to date | Intake test positive for codeine and morphine, negative for fentanyl, other opioids, benzodiazepines and other drugs; next at five weeks |
| Medication safety | Prescription drug monitoring program check | Before every controlled-substance prescription | Completed today | Checked today before buprenorphine: the codeine from two prescribers seen at intake and nothing new; the other prescriber informed with his consent |
| Medication safety | Naloxone at home and household staff trained | Every visit | Completed today | Naloxone at home; two of his staff shown how to use it |
| Survey | Pain intensity and interference (PEG) and function | Every visit | Up to date | PEG 6.7 at intake; repeat at five weeks |
| Referral | Physical therapy and graded activity | Twice weekly | Ordered | Physical therapy booked |
| Examination | Weight, meals and nutrition | Every visit | Completed today | 72.3 kg, BMI 19.8; dietitian next week |
| Laboratory | Kidney function, liver enzymes and albumin | At baseline and at about six months on scheduled acetaminophen | Up to date | Creatinine 0.94 mg/dL, eGFR 104, urine albumin-to-creatinine ratio 8 mg/g, AST 31, ALT 38 and albumin 3.7 g/dL at intake |
| Imaging | Hearing: audiometry, hearing aids and use | Audiometry once; hearing aid review after fitting | Ordered | Audiogram booked for the morning of the five-week visit |
| Referral | Psychiatry consultation | At diagnosis | Completed today | Seen by Dr. Bachmann-Adeyemi today |
Goal progress:
Guideline basis: Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder (2007); Guideline Watch (March 2013): Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder (Koran LM, Simpson HB), as reported by Psychiatric News (2013); Obsessive-compulsive disorder and body dysmorphic disorder: treatment (CG31) (2005); CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022 (2022); The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020); Prescription Drug Monitoring Programs (PDMPs) (2026); Hearing loss in adults: assessment and management (NG98) (2018); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)
Follow-up: Telephone check tomorrow after the second day of buprenorphine. Five-week review with the audiogram that morning. Call the clinic or 988 at any time; use naloxone and call 911 for heavy sleepiness or slow breathing. Next scheduled visit 2026-06-08: five-week review: OCD treatment, buprenorphine, pain, the audiogram and weight. [S]